Phio Pharmaceuticals Corp (PHIO) - Total Liabilities
Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) has total liabilities worth $950.00K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Phio Pharmaceuticals Corp (PHIO) investment intensity to see how much of total assets are deployed in long-term investments.
Phio Pharmaceuticals Corp - Total Liabilities Trend (2011–2025)
This chart illustrates how Phio Pharmaceuticals Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PHIO asset base.
Phio Pharmaceuticals Corp Competitors by Total Liabilities
The table below lists competitors of Phio Pharmaceuticals Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Natural Alternatives International
NASDAQ:NAII
|
USA | $86.25 Million |
|
Xelpmoc Design And Tech Limited
NSE:XELPMOC
|
India | Rs107.98 Million |
|
Volcano Bhd
KLSE:0232
|
Malaysia | RM52.09 Million |
|
S F Capital Bhd
KLSE:8745
|
Malaysia | RM65.21 Million |
|
5G Networks Ltd
AU:5GN
|
Australia | AU$25.82 Million |
|
Sanko Diecasting (Thailand) Public Company Limited
BK:SANKO
|
Thailand | ฿228.94 Million |
|
Basel Medical Group Ltd Ordinary Shares
NASDAQ:BMGL
|
USA | $11.99 Million |
|
Value8 N.V
AS:PREVA
|
Netherlands | €27.29 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Phio Pharmaceuticals Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Phio Pharmaceuticals Corp (PHIO) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 66.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Phio Pharmaceuticals Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Phio Pharmaceuticals Corp (2011–2025)
The table below shows the annual total liabilities of Phio Pharmaceuticals Corp from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.34 Million | +32.02% |
| 2024-12-31 | $1.01 Million | -37.88% |
| 2023-12-31 | $1.63 Million | -17.22% |
| 2022-12-31 | $1.97 Million | -39.04% |
| 2021-12-31 | $3.24 Million | +18.96% |
| 2020-12-31 | $2.72 Million | +18.81% |
| 2019-12-31 | $2.29 Million | +31.36% |
| 2018-12-31 | $1.74 Million | -23.00% |
| 2017-12-31 | $2.27 Million | -10.90% |
| 2016-12-31 | $2.54 Million | +12.03% |
| 2015-12-31 | $2.27 Million | -64.79% |
| 2014-12-31 | $6.44 Million | -35.53% |
| 2013-12-31 | $10.00 Million | -12.56% |
| 2012-12-31 | $11.43 Million | +401.18% |
| 2011-12-31 | $2.28 Million | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more